Lenvacent Capsule 4 mg contains Lenvatinib Mesylate, a potent oral tyrosine kinase inhibitor (TKI) used in the treatment of various advanced cancers. Lenvatinib is primarily indicated for patients with differentiated thyroid carcinoma (DTC), hepatocellular carcinoma (HCC), and renal cell carcinoma (RCC), particularly in cases where the disease is unresectable, progressive, or refractory to conventional therapies. Lenvacent represents a modern targeted therapy that inhibits multiple signaling pathways involved in tumor growth and angiogenesis.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted Cancer Therapy / Multi-Targeted Tyrosine Kinase Inhibitor

Pharmacology

Lenvatinib selectively inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor proliferation and angiogenesis. These include:

• VEGFR1, VEGFR2, VEGFR3 – regulating angiogenesis

• FGFR1-4 – promoting tumor cell proliferation

• PDGFRα, RET, and KIT – involved in tumor growth and survival

By inhibiting these RTKs, Lenvatinib disrupts both tumor blood supply and signaling pathways essential for cancer cell survival, leading to reduced tumor growth and angiogenesis.

Pharmacokinetics:

• Absorption: Rapid oral absorption with peak plasma concentration in 1–4 hours

• Protein binding: Approximately 98–99%

• Metabolism: Primarily hepatic via CYP3A4

• Elimination half-life: 28 hours

• Excretion: Predominantly in feces (65%) and urine (25%)

Indications

Lenvacent Capsule 4 mg is indicated for the treatment of:

• Differentiated thyroid carcinoma (DTC) that is progressive, locally recurrent, or metastatic

• Advanced hepatocellular carcinoma (HCC) in patients who are not candidates for transarterial chemoembolization

• Advanced renal cell carcinoma (RCC) in combination with everolimus after prior anti-angiogenic therapy

• Other solid tumors with specific molecular profiles as determined by the treating oncologist

Dosage and Administration

• Adults: The recommended starting dose is 4 mg orally once daily for patients who require lower-dose therapy due to toxicity or special clinical considerations

• Capsules should be swallowed whole with water, preferably at the same time each day

• Dose adjustments may be required in case of adverse reactions or hepatic/renal impairment

• Treatment is continued until disease progression or unacceptable toxicity occurs

Special Populations:

• Hepatic or renal impairment may require careful dose monitoring

• Geriatric patients may need individualized dosing

Contraindications

• Known hypersensitivity to Lenvatinib or any component of the formulation

• Pregnancy and breastfeeding (unless benefits outweigh risks)

Side Effects

Common adverse effects include:

• Hypertension

• Fatigue

• Diarrhea

• Nausea and vomiting

• Decreased appetite

• Weight loss

Serious but less common effects may include hepatotoxicity, proteinuria, cardiac dysfunction, and gastrointestinal perforation. Regular monitoring is recommended during therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Blood pressure should be monitored before and during therapy

• Liver and kidney function tests are recommended periodically

• Use caution in patients with cardiovascular risk factors or bleeding disorders

• Avoid use with strong CYP3A4 inhibitors or inducers unless clinically necessary

Pregnancy and Lactation

• Pregnancy Category D: Lenvatinib may cause fetal harm; effective contraception is required

• Breastfeeding should be avoided during treatment

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

Lenvacent Capsule 4 mg works by inhibiting multiple RTKs that regulate tumor growth, angiogenesis, and survival. By targeting both tumor cells and their supporting blood vessels, Lenvatinib provides a multi-faceted approach to controlling tumor progression, offering hope in advanced and refractory cancers.